Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression

Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while trichostatin A (TSA) is one of the most potent histone deacetylase (HDAC) inhibitors currently available. As both Nutlin-3 and TSA increase the l...

Full description

Saved in:
Bibliographic Details
Published inCell death & disease Vol. 4; no. 3; p. e533
Main Authors Sachweh, M C C, Drummond, C J, Higgins, M, Campbell, J, Laín, S
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2013
Springer Nature B.V
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while trichostatin A (TSA) is one of the most potent histone deacetylase (HDAC) inhibitors currently available. As both Nutlin-3 and TSA increase the levels of the cell cycle inhibitor p21(cip1/waf1) in cells, we investigated whether a combination of these compounds would further augment p21 levels. Contrary to expectations, we found that short-term exposure to Nutlin-3 and TSA in combination did not have an additive effect on p21 expression. Instead, we observed that activation of p53 prevented the ability of TSA to increase p21 levels. Furthermore, TSA inhibited Nutlin-3-induced expression of p53-dependent mRNAs including P21. This negative effect of TSA on Nutlin-3 was significantly less pronounced in the case of hdm2, another p53 downstream target. Aside from suggesting a model to explain these incompatible effects of Nutlin-3 and TSA, we discuss the implications of our findings in cancer therapy and cell reprogramming.
AbstractList Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while trichostatin A (TSA) is one of the most potent histone deacetylase (HDAC) inhibitors currently available. As both Nutlin-3 and TSA increase the levels of the cell cycle inhibitor p21(cip1/waf1) in cells, we investigated whether a combination of these compounds would further augment p21 levels. Contrary to expectations, we found that short-term exposure to Nutlin-3 and TSA in combination did not have an additive effect on p21 expression. Instead, we observed that activation of p53 prevented the ability of TSA to increase p21 levels. Furthermore, TSA inhibited Nutlin-3-induced expression of p53-dependent mRNAs including P21. This negative effect of TSA on Nutlin-3 was significantly less pronounced in the case of hdm2, another p53 downstream target. Aside from suggesting a model to explain these incompatible effects of Nutlin-3 and TSA, we discuss the implications of our findings in cancer therapy and cell reprogramming.
Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while trichostatin A (TSA) is one of the most potent histone deacetylase (HDAC) inhibitors currently available. As both Nutlin-3 and TSA increase the levels of the cell cycle inhibitor p21(cip1/waf1) in cells, we investigated whether a combination of these compounds would further augment p21 levels. Contrary to expectations, we found that short-term exposure to Nutlin-3 and TSA in combination did not have an additive effect on p21 expression. Instead, we observed that activation of p53 prevented the ability of TSA to increase p21 levels. Furthermore, TSA inhibited Nutlin-3-induced expression of p53-dependent mRNAs including P21. This negative effect of TSA on Nutlin-3 was significantly less pronounced in the case of hdm2, another p53 downstream target. Aside from suggesting a model to explain these incompatible effects of Nutlin-3 and TSA, we discuss the implications of our findings in cancer therapy and cell reprogramming.Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while trichostatin A (TSA) is one of the most potent histone deacetylase (HDAC) inhibitors currently available. As both Nutlin-3 and TSA increase the levels of the cell cycle inhibitor p21(cip1/waf1) in cells, we investigated whether a combination of these compounds would further augment p21 levels. Contrary to expectations, we found that short-term exposure to Nutlin-3 and TSA in combination did not have an additive effect on p21 expression. Instead, we observed that activation of p53 prevented the ability of TSA to increase p21 levels. Furthermore, TSA inhibited Nutlin-3-induced expression of p53-dependent mRNAs including P21. This negative effect of TSA on Nutlin-3 was significantly less pronounced in the case of hdm2, another p53 downstream target. Aside from suggesting a model to explain these incompatible effects of Nutlin-3 and TSA, we discuss the implications of our findings in cancer therapy and cell reprogramming.
Abstract Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while trichostatin A (TSA) is one of the most potent histone deacetylase (HDAC) inhibitors currently available. As both Nutlin-3 and TSA increase the levels of the cell cycle inhibitor p21(cip1/waf1) in cells, we investigated whether a combination of these compounds would further augment p21 levels. Contrary to expectations, we found that short-term exposure to Nutlin-3 and TSA in combination did not have an additive effect on p21 expression. Instead, we observed that activation of p53 prevented the ability of TSA to increase p21 levels. Furthermore, TSA inhibited Nutlin-3-induced expression of p53-dependent mRNAs including P21. This negative effect of TSA on Nutlin-3 was significantly less pronounced in the case of hdm2, another p53 downstream target. Aside from suggesting a model to explain these incompatible effects of Nutlin-3 and TSA, we discuss the implications of our findings in cancer therapy and cell reprogramming.
Author Sachweh, M C C
Higgins, M
Drummond, C J
Campbell, J
Laín, S
Author_xml – sequence: 1
  givenname: M C C
  surname: Sachweh
  fullname: Sachweh, M C C
  organization: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
– sequence: 2
  givenname: C J
  surname: Drummond
  fullname: Drummond, C J
  organization: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
– sequence: 3
  givenname: M
  surname: Higgins
  fullname: Higgins, M
  organization: Centre for Oncology and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School
– sequence: 4
  givenname: J
  surname: Campbell
  fullname: Campbell, J
  organization: Centre for Oncology and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School
– sequence: 5
  givenname: S
  surname: Laín
  fullname: Laín, S
  email: sonia.lain@ki.se
  organization: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Centre for Oncology and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23470540$$D View this record in MEDLINE/PubMed
http://kipublications.ki.se/Default.aspx?queryparsed=id:126473389$$DView record from Swedish Publication Index
BookMark eNqFks9rFDEUx4NUbF179CoBL152zc9J5iKU1dpCwYvehDCTedmmziZjMqv2v2_GTtutKCaBhLzP95uXx3uODkIMgNBLSlaUcP3Wdp3PK0YoX1X0CTpiRNCl0Lo-2DsfouOcr0gZnBMmq2fokHGhiBTkCH09DzZuh2b0bQ8YnAM7ZhwdHiTHTejw2fuTNfbh0rd-9DHgsgZGMfwaEuQ83UyUhb7H9toWjyHFzRx6gZ66ps9wPO8L9OX0w-f12fLi08fz9cnF0kolx5JkW0kNRFugVJHWglZKsDJBSydsK7iSle6cJVY57kjtGl0LRzkoWRR8gZa3vvknDLvWDMlvm3RtYuPNfPWtnMBITmo28fU_-ZJ-9yC6E1JWCcW5rov23a22AFvoLIQxNf1ji0eR4C_NJv4wvKJc88ngzWyQ4vcd5NFsfZ7q1wSIu2yoqknNa1nx_6OcFoxJxQr6-g_0Ku5SKFUvhrqioiKSPRTKpphzAnefNyVm6ijzu6PM1FGm5LtAr_Y_e0_f9U8BVnMlSyhsIO09-1fHG_ue2JA
CitedBy_id crossref_primary_10_1007_s10238_015_0400_3
crossref_primary_10_1002_biof_1544
crossref_primary_10_1093_jmcb_mjz006
crossref_primary_10_1016_j_abb_2014_01_022
crossref_primary_10_3390_cancers11010003
crossref_primary_10_3892_or_2016_4636
crossref_primary_10_1038_cddis_2015_328
crossref_primary_10_18632_oncotarget_18910
crossref_primary_10_18632_oncotarget_2667
crossref_primary_10_18632_oncotarget_2668
crossref_primary_10_1371_journal_pone_0186208
crossref_primary_10_3389_fonc_2022_994172
crossref_primary_10_4068_cmj_2016_52_1_1
crossref_primary_10_18632_oncotarget_5891
crossref_primary_10_3892_mmr_2014_2517
crossref_primary_10_1007_s13277_015_3879_z
crossref_primary_10_1089_dna_2017_3686
crossref_primary_10_1002_jcb_29324
crossref_primary_10_3892_ijo_2017_4095
crossref_primary_10_1186_1476_4598_13_116
crossref_primary_10_1080_07391102_2017_1302820
crossref_primary_10_1155_2014_348728
crossref_primary_10_1002_jcp_27798
crossref_primary_10_1016_j_matpr_2020_04_015
crossref_primary_10_1097_CAD_0000000000000935
crossref_primary_10_1038_bjc_2017_433
crossref_primary_10_1038_onc_2016_344
Cites_doi 10.1158/0008-5472.CAN-06-1527
10.1093/hmg/ddm052
10.1038/nature08311
10.1158/1541-7786.MCR-07-0161
10.1111/j.1749-6632.1999.tb09415.x
10.1158/0008-5472.CAN-04-3576
10.1016/j.bbrc.2004.09.130
10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5
10.4161/cc.20254
10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9
10.1073/pnas.98.1.87
10.1073/pnas.97.7.3260
10.1128/MCB.13.3.1415
10.1093/emboj/17.17.5001
10.1038/onc.2010.413
10.1074/jbc.M508270200
10.1016/0022-1759(92)90122-A
10.1126/science.1092472
10.1128/MCB.25.1.147-161.2005
10.1016/j.bbrc.2008.11.057
10.1038/cdd.2010.18
10.1126/science.282.5393.1497
10.1016/j.bbrc.2005.07.039
10.1634/stemcells.2007-0649
10.1073/pnas.081074898
10.1093/nar/gkj462
10.4161/epi.6.8.16065
10.1111/j.1600-0749.2005.00225.x
10.1038/nbt1418
10.1038/sj.onc.1202014
10.1073/pnas.150006697
10.1038/nbt1272
10.4161/cc.10.10.15519
10.1074/jbc.275.2.1371
10.1098/rstb.2011.0016
10.1093/nar/gki177
10.1126/science.288.5468.1053
10.1128/MCB.13.7.4107
10.1073/pnas.0813333106
10.1002/ijc.20968
10.1242/jcs.108.8.2801
ContentType Journal Article
Copyright The Author(s) 2013
Copyright Nature Publishing Group Mar 2013
Copyright © 2013 Macmillan Publishers Limited 2013 Macmillan Publishers Limited
Copyright_xml – notice: The Author(s) 2013
– notice: Copyright Nature Publishing Group Mar 2013
– notice: Copyright © 2013 Macmillan Publishers Limited 2013 Macmillan Publishers Limited
DBID C6C
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
88A
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M2P
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
7TO
H94
5PM
ADTPV
AOWAS
D8T
ZZAVC
DOI 10.1038/cddis.2013.61
DatabaseName SpringerOpen (Open Access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Science Database
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Freely available online
SwePub Articles full text
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitleList Publicly Available Content Database

MEDLINE - Academic

CrossRef
MEDLINE
Oncogenes and Growth Factors Abstracts
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen (Open Access)
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Trichostatin A inhibits p53 and vice versa
EISSN 2041-4889
EndPage e533
ExternalDocumentID oai_swepub_ki_se_530927
oai_prod_swepub_kib_ki_se_126473389
4042501821
10_1038_cddis_2013_61
23470540
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Cancer Research UK
  grantid: C8/A6613
GroupedDBID ---
0R~
3V.
53G
5VS
70F
7X7
88A
88I
8FE
8FH
8FI
8FJ
AAJSJ
ABAWZ
ABUWG
ACGFS
ACSMW
ADBBV
ADRAZ
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CAG
CCPQU
COF
DIK
DWQXO
E3Z
EBLON
EBS
EJD
EMOBN
FRP
FYUFA
GNUQQ
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
HZ~
IPNFZ
KQ8
LK8
M0L
M2P
M48
M7P
M~E
NAO
O5R
O5S
O9-
OK1
PIMPY
PQQKQ
PROAC
RIG
RNT
RPM
SNYQT
TR2
UKHRP
W2D
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7XB
8FK
K9.
PQEST
PQUKI
PRINS
Q9U
7X8
7TO
H94
5PM
ADTPV
AOWAS
D8T
ZZAVC
ID FETCH-LOGICAL-c575t-48b658e08ce1170bce87742424e85f4cb437568dfc0c7f3f09fa894f13e751173
IEDL.DBID RPM
ISSN 2041-4889
IngestDate Thu Nov 07 05:31:01 EST 2024
Wed Oct 30 04:46:37 EDT 2024
Tue Sep 17 21:17:52 EDT 2024
Fri Oct 25 07:07:53 EDT 2024
Sat Oct 26 04:37:16 EDT 2024
Thu Oct 10 19:31:51 EDT 2024
Fri Aug 23 01:18:47 EDT 2024
Sat Nov 02 11:58:07 EDT 2024
Fri Oct 11 20:48:32 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Nutlin-3
cancer therapy
iPS cell generation
trichostatin A
p21
p53
Language English
License This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c575t-48b658e08ce1170bce87742424e85f4cb437568dfc0c7f3f09fa894f13e751173
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613839/
PMID 23470540
PQID 1786146052
PQPubID 2041963
ParticipantIDs swepub_primary_oai_swepub_ki_se_530927
swepub_primary_oai_prod_swepub_kib_ki_se_126473389
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3613839
proquest_miscellaneous_1790939563
proquest_miscellaneous_1315632572
proquest_journals_1786146052
crossref_primary_10_1038_cddis_2013_61
pubmed_primary_23470540
springer_journals_10_1038_cddis_2013_61
PublicationCentury 2000
PublicationDate 2013-03-01
PublicationDateYYYYMMDD 2013-03-01
PublicationDate_xml – month: 03
  year: 2013
  text: 2013-03-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Cell death & disease
PublicationTitleAbbrev Cell Death Dis
PublicationTitleAlternate Cell Death Dis
PublicationYear 2013
Publisher Nature Publishing Group UK
Springer Nature B.V
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Springer Nature B.V
– name: Nature Publishing Group
References Noh, Lim, Jeong, Lee (CR17) 2009; 378
Frebourg, Barbier, Kassel, Ng, Romero, Friend (CR46) 1992; 52
Oda, Ohki, Murasawa, Nemoto, Shibue, Yamashita (CR13) 2000; 288
Cheok, Kua, Kaldis, Lane (CR22) 2010; 17
Sowa, Orita, Hiranabe-Minamikawa, Nakano, Mizuno, Nomura (CR10) 1999; 886
Kemp, Ghosh, Liu, Leffak (CR15) 2005; 33
Kranz, Dobbelstein (CR20) 2006; 66
Vassilev, Vu, Graves, Carvajal, Podlaski, Filipovic (CR2) 2004; 303
Weber, Liu, Collins, Levens (CR28) 2005; 25
Stott, Bates, James, McConnell, Starborg, Brookes (CR25) 1998; 17
Chen, Marechal, Levine (CR42) 1993; 13
Huangfu, Maehr, Guo, Eijkelenboom, Snitow, Chen (CR36) 2008; 26
van Leeuwen, Higgins, Campbell, Brown, McCarthy, Pirrie (CR4) 2011; 10
Wu, Meng, Wang, Zhou, Xu, Wang (CR9) 2005; 335
Coller, Grandori, Tamayo, Colbert, Lander, Eisenman (CR31) 2000; 97
Xia, Knezevic, Vassilev (CR14) 2011; 30
Peltonen, Kiviharju, Jarvinen, Ra, Laiho (CR5) 2005; 18
Bickmore, Carothers (CR16) 1995; 108
Sur, Pagliarini, Bunz, Rago, Diaz, Kinzler (CR21) 2009; 106
Gartel, Ye, Goufman, Shianov, Hay, Najmabadi (CR32) 2001; 98
Claassen, Hann (CR30) 2000; 97
Matheu, Klatt, Serrano (CR24) 2005; 280
van Leeuwen, Rao, Sachweh, Lain (CR23) 2012; 11
Yonish-Rouach, Grunwald, Wilder, Kimchi, May, Lawrence (CR34) 1993; 13
Gialitakis, Kretsovali, Spilianakis, Kravariti, Mages, Hoffmann (CR6) 2006; 34
Xiao, Hasegawa, Isobe (CR12) 1999; 73
Furumai, Komatsu, Nishino, Khochbin, Yoshida, Horinouchi (CR18) 2001; 98
Okita, Yamanaka (CR38) 2011; 366
Suzuki, Yokozaki, Kuniyasu, Hayashi, Naka, Ono (CR8) 2000; 88
Vojtesek, Bartek, Midgley, Lane (CR44) 1992; 151
Cheok, Dey, Lane (CR3) 2007; 5
Li, Wu (CR27) 2004; 324
Mitchell, El-Deiry (CR29) 1999; 10
Bunz, Dutriaux, Lengauer, Waldman, Zhou, Brown (CR41) 1998; 282
Chen, Li (CR26) 2011; 6
Kawamura, Suzuki, Wang, Menendez, Morera, Raya (CR39) 2009; 460
Ruau, Ensenat-Waser, Dinger, Vallabhapurapu, Rolletschek, Hacker (CR37) 2008; 26
Blaydes, Hupp (CR40) 1998; 17
Blagosklonny, Robey, Sackett, Du, Traganos, Darzynkiewicz (CR7) 2002; 1
Ragimov, Krauskopf, Navot, Rotter, Oren, Aloni (CR33) 1993; 8
Fredersdorf, Milne, Hall, Lu (CR43) 1996; 148
Berkson, Hollick, Westwood, Woods, Lane, Lain (CR45) 2005; 115
Xiao, Hasegawa, Isobe (CR11) 2000; 275
Marks, Breslow (CR1) 2007; 25
Carvajal, Tovar, Yang, Vu, Heimbrook, Vassilev (CR19) 2005; 65
Gudkov, Komarova (CR35) 2007; 16
PA Marks (BFcddis201361_CR1) 2007; 25
E Yonish-Rouach (BFcddis201361_CR34) 1993; 13
E Oda (BFcddis201361_CR13) 2000; 288
LT Vassilev (BFcddis201361_CR2) 2004; 303
Y Sowa (BFcddis201361_CR10) 1999; 886
D Carvajal (BFcddis201361_CR19) 2005; 65
HA Coller (BFcddis201361_CR31) 2000; 97
F Bunz (BFcddis201361_CR41) 1998; 282
R Furumai (BFcddis201361_CR18) 2001; 98
M Xia (BFcddis201361_CR14) 2011; 30
K Peltonen (BFcddis201361_CR5) 2005; 18
CF Cheok (BFcddis201361_CR22) 2010; 17
EJ Noh (BFcddis201361_CR17) 2009; 378
S Sur (BFcddis201361_CR21) 2009; 106
M Gialitakis (BFcddis201361_CR6) 2006; 34
D Kranz (BFcddis201361_CR20) 2006; 66
P Wu (BFcddis201361_CR9) 2005; 335
H Xiao (BFcddis201361_CR11) 2000; 275
D Huangfu (BFcddis201361_CR36) 2008; 26
FJ Stott (BFcddis201361_CR25) 1998; 17
T Kawamura (BFcddis201361_CR39) 2009; 460
B Vojtesek (BFcddis201361_CR44) 1992; 151
H Xiao (BFcddis201361_CR12) 1999; 73
WA Bickmore (BFcddis201361_CR16) 1995; 108
KO Mitchell (BFcddis201361_CR29) 1999; 10
J Chen (BFcddis201361_CR42) 1993; 13
GF Claassen (BFcddis201361_CR30) 2000; 97
MV Blagosklonny (BFcddis201361_CR7) 2002; 1
IM van Leeuwen (BFcddis201361_CR4) 2011; 10
A Weber (BFcddis201361_CR28) 2005; 25
AV Gudkov (BFcddis201361_CR35) 2007; 16
D Ruau (BFcddis201361_CR37) 2008; 26
S Fredersdorf (BFcddis201361_CR43) 1996; 148
T Frebourg (BFcddis201361_CR46) 1992; 52
RG Berkson (BFcddis201361_CR45) 2005; 115
J Chen (BFcddis201361_CR26) 2011; 6
AL Gartel (BFcddis201361_CR32) 2001; 98
IM van Leeuwen (BFcddis201361_CR23) 2012; 11
JP Blaydes (BFcddis201361_CR40) 1998; 17
T Suzuki (BFcddis201361_CR8) 2000; 88
MG Kemp (BFcddis201361_CR15) 2005; 33
K Okita (BFcddis201361_CR38) 2011; 366
N Ragimov (BFcddis201361_CR33) 1993; 8
A Matheu (BFcddis201361_CR24) 2005; 280
H Li (BFcddis201361_CR27) 2004; 324
CF Cheok (BFcddis201361_CR3) 2007; 5
References_xml – volume: 66
  start-page: 10274
  year: 2006
  end-page: 10280
  ident: CR20
  article-title: Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1527
  contributor:
    fullname: Dobbelstein
– volume: 16
  start-page: R67
  year: 2007
  end-page: R72
  ident: CR35
  article-title: Dangerous habits of a security guard: the two faces of p53 as a drug target
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddm052
  contributor:
    fullname: Komarova
– volume: 460
  start-page: 1140
  year: 2009
  end-page: 1144
  ident: CR39
  article-title: Linking the p53 tumour suppressor pathway to somatic cell reprogramming
  publication-title: Nature
  doi: 10.1038/nature08311
  contributor:
    fullname: Raya
– volume: 5
  start-page: 1133
  year: 2007
  end-page: 1145
  ident: CR3
  article-title: Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-07-0161
  contributor:
    fullname: Lane
– volume: 886
  start-page: 195
  year: 1999
  end-page: 199
  ident: CR10
  article-title: Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites
  publication-title: Ann NY Acad Sci
  doi: 10.1111/j.1749-6632.1999.tb09415.x
  contributor:
    fullname: Nomura
– volume: 65
  start-page: 1918
  year: 2005
  end-page: 1924
  ident: CR19
  article-title: Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-3576
  contributor:
    fullname: Vassilev
– volume: 324
  start-page: 860
  year: 2004
  end-page: 867
  ident: CR27
  article-title: Histone deacetylase inhibitor, trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2004.09.130
  contributor:
    fullname: Wu
– volume: 73
  start-page: 291
  year: 1999
  end-page: 302
  ident: CR12
  article-title: Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells
  publication-title: J Cell Biochem
  doi: 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5
  contributor:
    fullname: Isobe
– volume: 11
  start-page: 1851
  year: 2012
  end-page: 1861
  ident: CR23
  article-title: An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anti-cancer drugs in normal cells
  publication-title: Cell Cycle
  doi: 10.4161/cc.20254
  contributor:
    fullname: Lain
– volume: 88
  start-page: 992
  year: 2000
  end-page: 997
  ident: CR8
  article-title: Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines
  publication-title: Int J Cancer
  doi: 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9
  contributor:
    fullname: Ono
– volume: 98
  start-page: 87
  year: 2001
  end-page: 92
  ident: CR18
  article-title: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.98.1.87
  contributor:
    fullname: Horinouchi
– volume: 97
  start-page: 3260
  year: 2000
  end-page: 3265
  ident: CR31
  article-title: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.97.7.3260
  contributor:
    fullname: Eisenman
– volume: 13
  start-page: 1415
  year: 1993
  end-page: 1423
  ident: CR34
  article-title: P53-mediated cell death: relationship to cell cycle control
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.13.3.1415
  contributor:
    fullname: Lawrence
– volume: 17
  start-page: 5001
  year: 1998
  end-page: 5014
  ident: CR25
  article-title: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
  publication-title: EMBO J
  doi: 10.1093/emboj/17.17.5001
  contributor:
    fullname: Brookes
– volume: 30
  start-page: 346
  year: 2011
  end-page: 355
  ident: CR14
  article-title: P21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
  publication-title: Oncogene
  doi: 10.1038/onc.2010.413
  contributor:
    fullname: Vassilev
– volume: 10
  start-page: 223
  year: 1999
  end-page: 230
  ident: CR29
  article-title: Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12- -tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells
  publication-title: Cell Growth Differ
  contributor:
    fullname: El-Deiry
– volume: 148
  start-page: 825
  year: 1996
  end-page: 835
  ident: CR43
  article-title: Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues
  publication-title: Am J Pathol
  contributor:
    fullname: Lu
– volume: 280
  start-page: 42433
  year: 2005
  end-page: 42441
  ident: CR24
  article-title: Regulation of the INK4a/ARF locus by histone deacetylase inhibitors
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M508270200
  contributor:
    fullname: Serrano
– volume: 151
  start-page: 237
  year: 1992
  end-page: 244
  ident: CR44
  article-title: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53
  publication-title: J Immunol Methods
  doi: 10.1016/0022-1759(92)90122-A
  contributor:
    fullname: Lane
– volume: 303
  start-page: 844
  year: 2004
  end-page: 848
  ident: CR2
  article-title: activation of the p53 pathway by small-molecule antagonists of MDM2
  publication-title: Science
  doi: 10.1126/science.1092472
  contributor:
    fullname: Filipovic
– volume: 25
  start-page: 147
  year: 2005
  end-page: 161
  ident: CR28
  article-title: TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.25.1.147-161.2005
  contributor:
    fullname: Levens
– volume: 378
  start-page: 326
  year: 2009
  end-page: 331
  ident: CR17
  article-title: An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2008.11.057
  contributor:
    fullname: Lee
– volume: 17
  start-page: 1486
  year: 2010
  end-page: 1500
  ident: CR22
  article-title: Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2010.18
  contributor:
    fullname: Lane
– volume: 282
  start-page: 1497
  year: 1998
  end-page: 1501
  ident: CR41
  article-title: Requirement for p53 and p21 to sustain G2 arrest after DNA damage
  publication-title: Science
  doi: 10.1126/science.282.5393.1497
  contributor:
    fullname: Brown
– volume: 1
  start-page: 937
  year: 2002
  end-page: 941
  ident: CR7
  article-title: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity
  publication-title: Mol Cancer Ther
  contributor:
    fullname: Darzynkiewicz
– volume: 335
  start-page: 36
  year: 2005
  end-page: 44
  ident: CR9
  article-title: Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2005.07.039
  contributor:
    fullname: Wang
– volume: 26
  start-page: 920
  year: 2008
  end-page: 926
  ident: CR37
  article-title: Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells
  publication-title: Stem Cells
  doi: 10.1634/stemcells.2007-0649
  contributor:
    fullname: Hacker
– volume: 98
  start-page: 4510
  year: 2001
  end-page: 4515
  ident: CR32
  article-title: Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.081074898
  contributor:
    fullname: Najmabadi
– volume: 34
  start-page: 765
  year: 2006
  end-page: 772
  ident: CR6
  article-title: Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by trichostatin A
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkj462
  contributor:
    fullname: Hoffmann
– volume: 6
  start-page: 957
  year: 2011
  end-page: 961
  ident: CR26
  article-title: Life and death of transcriptional co-activator p300
  publication-title: Epigenetics
  doi: 10.4161/epi.6.8.16065
  contributor:
    fullname: Li
– volume: 18
  start-page: 196
  year: 2005
  end-page: 202
  ident: CR5
  article-title: Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis
  publication-title: Pigment Cell Res
  doi: 10.1111/j.1600-0749.2005.00225.x
  contributor:
    fullname: Laiho
– volume: 26
  start-page: 795
  year: 2008
  end-page: 797
  ident: CR36
  article-title: Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1418
  contributor:
    fullname: Chen
– volume: 17
  start-page: 1045
  year: 1998
  end-page: 1052
  ident: CR40
  article-title: DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1202014
  contributor:
    fullname: Hupp
– volume: 8
  start-page: 1183
  year: 1993
  end-page: 1193
  ident: CR33
  article-title: Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif
  publication-title: Oncogene
  contributor:
    fullname: Aloni
– volume: 97
  start-page: 9498
  year: 2000
  end-page: 9503
  ident: CR30
  article-title: A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.150006697
  contributor:
    fullname: Hann
– volume: 25
  start-page: 84
  year: 2007
  end-page: 90
  ident: CR1
  article-title: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1272
  contributor:
    fullname: Breslow
– volume: 10
  start-page: 1590
  year: 2011
  end-page: 1598
  ident: CR4
  article-title: Mechanism-specific signatures for small-molecule p53 activators
  publication-title: Cell Cycle
  doi: 10.4161/cc.10.10.15519
  contributor:
    fullname: Pirrie
– volume: 275
  start-page: 1371
  year: 2000
  end-page: 1376
  ident: CR11
  article-title: P300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor
  publication-title: J Biol Chem
  doi: 10.1074/jbc.275.2.1371
  contributor:
    fullname: Isobe
– volume: 52
  start-page: 6976
  year: 1992
  end-page: 6978
  ident: CR46
  article-title: A functional screen for germ line p53 mutations based on transcriptional activation
  publication-title: Cancer Res
  contributor:
    fullname: Friend
– volume: 366
  start-page: 2198
  year: 2011
  end-page: 2207
  ident: CR38
  article-title: Induced pluripotent stem cells: opportunities and challenges
  publication-title: Philos Trans R Soc Lond Ser B
  doi: 10.1098/rstb.2011.0016
  contributor:
    fullname: Yamanaka
– volume: 33
  start-page: 325
  year: 2005
  end-page: 336
  ident: CR15
  article-title: The histone deacetylase inhibitor trichostatin A alters the pattern of DNA replication origin activity in human cells
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gki177
  contributor:
    fullname: Leffak
– volume: 288
  start-page: 1053
  year: 2000
  end-page: 1058
  ident: CR13
  article-title: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
  publication-title: Science
  doi: 10.1126/science.288.5468.1053
  contributor:
    fullname: Yamashita
– volume: 13
  start-page: 4107
  year: 1993
  end-page: 4114
  ident: CR42
  article-title: Mapping of the p53 and mdm-2 interaction domains
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.13.7.4107
  contributor:
    fullname: Levine
– volume: 108
  start-page: 2801
  issue: Part 8
  year: 1995
  end-page: 2809
  ident: CR16
  article-title: Factors affecting the timing and imprinting of replication on a mammalian chromosome
  publication-title: J Cell Sci
  contributor:
    fullname: Carothers
– volume: 106
  start-page: 3964
  year: 2009
  end-page: 3969
  ident: CR21
  article-title: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0813333106
  contributor:
    fullname: Kinzler
– volume: 115
  start-page: 701
  year: 2005
  end-page: 710
  ident: CR45
  article-title: Pilot screening programme for small molecule activators of p53
  publication-title: Int J Cancer
  doi: 10.1002/ijc.20968
  contributor:
    fullname: Lain
– volume: 282
  start-page: 1497
  year: 1998
  ident: BFcddis201361_CR41
  publication-title: Science
  doi: 10.1126/science.282.5393.1497
  contributor:
    fullname: F Bunz
– volume: 148
  start-page: 825
  year: 1996
  ident: BFcddis201361_CR43
  publication-title: Am J Pathol
  contributor:
    fullname: S Fredersdorf
– volume: 378
  start-page: 326
  year: 2009
  ident: BFcddis201361_CR17
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2008.11.057
  contributor:
    fullname: EJ Noh
– volume: 115
  start-page: 701
  year: 2005
  ident: BFcddis201361_CR45
  publication-title: Int J Cancer
  doi: 10.1002/ijc.20968
  contributor:
    fullname: RG Berkson
– volume: 108
  start-page: 2801
  issue: Part 8
  year: 1995
  ident: BFcddis201361_CR16
  publication-title: J Cell Sci
  doi: 10.1242/jcs.108.8.2801
  contributor:
    fullname: WA Bickmore
– volume: 18
  start-page: 196
  year: 2005
  ident: BFcddis201361_CR5
  publication-title: Pigment Cell Res
  doi: 10.1111/j.1600-0749.2005.00225.x
  contributor:
    fullname: K Peltonen
– volume: 26
  start-page: 795
  year: 2008
  ident: BFcddis201361_CR36
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1418
  contributor:
    fullname: D Huangfu
– volume: 6
  start-page: 957
  year: 2011
  ident: BFcddis201361_CR26
  publication-title: Epigenetics
  doi: 10.4161/epi.6.8.16065
  contributor:
    fullname: J Chen
– volume: 16
  start-page: R67
  year: 2007
  ident: BFcddis201361_CR35
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddm052
  contributor:
    fullname: AV Gudkov
– volume: 10
  start-page: 223
  year: 1999
  ident: BFcddis201361_CR29
  publication-title: Cell Growth Differ
  contributor:
    fullname: KO Mitchell
– volume: 88
  start-page: 992
  year: 2000
  ident: BFcddis201361_CR8
  publication-title: Int J Cancer
  doi: 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9
  contributor:
    fullname: T Suzuki
– volume: 97
  start-page: 3260
  year: 2000
  ident: BFcddis201361_CR31
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.97.7.3260
  contributor:
    fullname: HA Coller
– volume: 5
  start-page: 1133
  year: 2007
  ident: BFcddis201361_CR3
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-07-0161
  contributor:
    fullname: CF Cheok
– volume: 151
  start-page: 237
  year: 1992
  ident: BFcddis201361_CR44
  publication-title: J Immunol Methods
  doi: 10.1016/0022-1759(92)90122-A
  contributor:
    fullname: B Vojtesek
– volume: 13
  start-page: 1415
  year: 1993
  ident: BFcddis201361_CR34
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.13.3.1415
  contributor:
    fullname: E Yonish-Rouach
– volume: 98
  start-page: 4510
  year: 2001
  ident: BFcddis201361_CR32
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.081074898
  contributor:
    fullname: AL Gartel
– volume: 10
  start-page: 1590
  year: 2011
  ident: BFcddis201361_CR4
  publication-title: Cell Cycle
  doi: 10.4161/cc.10.10.15519
  contributor:
    fullname: IM van Leeuwen
– volume: 30
  start-page: 346
  year: 2011
  ident: BFcddis201361_CR14
  publication-title: Oncogene
  doi: 10.1038/onc.2010.413
  contributor:
    fullname: M Xia
– volume: 25
  start-page: 147
  year: 2005
  ident: BFcddis201361_CR28
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.25.1.147-161.2005
  contributor:
    fullname: A Weber
– volume: 17
  start-page: 1045
  year: 1998
  ident: BFcddis201361_CR40
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1202014
  contributor:
    fullname: JP Blaydes
– volume: 8
  start-page: 1183
  year: 1993
  ident: BFcddis201361_CR33
  publication-title: Oncogene
  contributor:
    fullname: N Ragimov
– volume: 106
  start-page: 3964
  year: 2009
  ident: BFcddis201361_CR21
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0813333106
  contributor:
    fullname: S Sur
– volume: 335
  start-page: 36
  year: 2005
  ident: BFcddis201361_CR9
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2005.07.039
  contributor:
    fullname: P Wu
– volume: 98
  start-page: 87
  year: 2001
  ident: BFcddis201361_CR18
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.98.1.87
  contributor:
    fullname: R Furumai
– volume: 66
  start-page: 10274
  year: 2006
  ident: BFcddis201361_CR20
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1527
  contributor:
    fullname: D Kranz
– volume: 25
  start-page: 84
  year: 2007
  ident: BFcddis201361_CR1
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1272
  contributor:
    fullname: PA Marks
– volume: 73
  start-page: 291
  year: 1999
  ident: BFcddis201361_CR12
  publication-title: J Cell Biochem
  doi: 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5
  contributor:
    fullname: H Xiao
– volume: 17
  start-page: 1486
  year: 2010
  ident: BFcddis201361_CR22
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2010.18
  contributor:
    fullname: CF Cheok
– volume: 17
  start-page: 5001
  year: 1998
  ident: BFcddis201361_CR25
  publication-title: EMBO J
  doi: 10.1093/emboj/17.17.5001
  contributor:
    fullname: FJ Stott
– volume: 275
  start-page: 1371
  year: 2000
  ident: BFcddis201361_CR11
  publication-title: J Biol Chem
  doi: 10.1074/jbc.275.2.1371
  contributor:
    fullname: H Xiao
– volume: 34
  start-page: 765
  year: 2006
  ident: BFcddis201361_CR6
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkj462
  contributor:
    fullname: M Gialitakis
– volume: 280
  start-page: 42433
  year: 2005
  ident: BFcddis201361_CR24
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M508270200
  contributor:
    fullname: A Matheu
– volume: 13
  start-page: 4107
  year: 1993
  ident: BFcddis201361_CR42
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.13.7.4107
  contributor:
    fullname: J Chen
– volume: 303
  start-page: 844
  year: 2004
  ident: BFcddis201361_CR2
  publication-title: Science
  doi: 10.1126/science.1092472
  contributor:
    fullname: LT Vassilev
– volume: 26
  start-page: 920
  year: 2008
  ident: BFcddis201361_CR37
  publication-title: Stem Cells
  doi: 10.1634/stemcells.2007-0649
  contributor:
    fullname: D Ruau
– volume: 324
  start-page: 860
  year: 2004
  ident: BFcddis201361_CR27
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2004.09.130
  contributor:
    fullname: H Li
– volume: 97
  start-page: 9498
  year: 2000
  ident: BFcddis201361_CR30
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.150006697
  contributor:
    fullname: GF Claassen
– volume: 288
  start-page: 1053
  year: 2000
  ident: BFcddis201361_CR13
  publication-title: Science
  doi: 10.1126/science.288.5468.1053
  contributor:
    fullname: E Oda
– volume: 460
  start-page: 1140
  year: 2009
  ident: BFcddis201361_CR39
  publication-title: Nature
  doi: 10.1038/nature08311
  contributor:
    fullname: T Kawamura
– volume: 886
  start-page: 195
  year: 1999
  ident: BFcddis201361_CR10
  publication-title: Ann NY Acad Sci
  doi: 10.1111/j.1749-6632.1999.tb09415.x
  contributor:
    fullname: Y Sowa
– volume: 1
  start-page: 937
  year: 2002
  ident: BFcddis201361_CR7
  publication-title: Mol Cancer Ther
  contributor:
    fullname: MV Blagosklonny
– volume: 52
  start-page: 6976
  year: 1992
  ident: BFcddis201361_CR46
  publication-title: Cancer Res
  contributor:
    fullname: T Frebourg
– volume: 11
  start-page: 1851
  year: 2012
  ident: BFcddis201361_CR23
  publication-title: Cell Cycle
  doi: 10.4161/cc.20254
  contributor:
    fullname: IM van Leeuwen
– volume: 33
  start-page: 325
  year: 2005
  ident: BFcddis201361_CR15
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gki177
  contributor:
    fullname: MG Kemp
– volume: 65
  start-page: 1918
  year: 2005
  ident: BFcddis201361_CR19
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-3576
  contributor:
    fullname: D Carvajal
– volume: 366
  start-page: 2198
  year: 2011
  ident: BFcddis201361_CR38
  publication-title: Philos Trans R Soc Lond Ser B
  doi: 10.1098/rstb.2011.0016
  contributor:
    fullname: K Okita
SSID ssj0000330256
Score 2.1904733
Snippet Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while...
Abstract Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2),...
SourceID swepub
pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage e533
SubjectTerms 631/80/641
692/699/67/1059
692/699/67/581
Antibodies
Biochemistry
Biomedical and Life Sciences
Cell Biology
Cell Culture
Cell Cycle Checkpoints - drug effects
Cyclin-Dependent Kinase Inhibitor p21 - genetics
Cyclin-Dependent Kinase Inhibitor p21 - metabolism
HCT116 Cells
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylases - chemistry
Histone Deacetylases - metabolism
Humans
Hydroxamic Acids - pharmacology
Imidazoles - pharmacology
Immunology
Life Sciences
MCF-7 Cells
Medicin och hälsovetenskap
Original
original-article
Piperazines - pharmacology
Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors
Proto-Oncogene Proteins c-mdm2 - metabolism
RNA, Messenger - metabolism
Tumor Suppressor Protein p53 - antagonists & inhibitors
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fi9QwEB50D8EX8bfVUyKIPtVrOmmTPsl53rEIHiIe3IMQ0jTlitJd3T3w_ntn2mx1veOgfWmmbTqTZL4kX2cAXtW6kVKjSkPeBE5hlqWuxDr12hl0jlyM4x-cPx2X8xP18bQ4jQtuq0ir3IyJw0DdLDyvke9JbciTEPjO3y1_ppw1indXYwqNm7CT00whm8HO-8Pjz1-mVZaMpuvk1GNwzQzNnmeaDlO68G0pt53RJYR5mSg57Zb-F1l08EZHd-FOhJFif7T7PbgR-vtwa0wsefEAvlG3546-7uofQUTOhli0YlmgcH0j5h_2D0TXn3X1QNkSdCxzKcLvyIvtByle1Rf-gt4gBh7XWPQQTo4Ovx7M05hHIfUExtapMjXhjJAZHzjPTO2DIdDH_4UEU7TK1wp1UZqm9ZnXLbZZ1TpTqVZi0AVb8hHM-kUfnoAgjy4VmbfCxilN4KbMK6l8qZwqQqNCAq83CrXLMVyGHba50dhB85Y1b0uZwO5G3Tb2mpX9a-MEXk7F1N75c10fFuckgzTjRBporpPRVVYhzfwwgcejBafa5Kg0w9QE9JZtJwGOt71d0ndnQ9xtJOhDeDKBN5tW8E_Vr_7IfGwk2w8nz2jj9e8dn3YVrCRkqpHgI6nwipsmeZYtMKty_fR6FT6D2_mQuoP5crswW_86D88JQK3rF7GX_AG3gR28
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals (Open Access)
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBYlpdBLSdOXmzQoUNqTU0sjW_KhlJAmLIX21IUcCkKWZWISvNtkA9l_3xnZ63a7SynYF2tsS6PHfGN_mmHsbaVrITSoNMg6UAqzLHUFVKnXzoBzaGIcbXD--q2YTNWXi_zid0ihQYG3W107yic1vbk-vv-5_IQT_mO_Zdx88MS8IZYWHJMj9FAqdNKJxTcg_bgo4yUZc7nKTKHXZEw5RNzceMK6hdqAnZvsyfEX6l_hRqOJOt9lTwZsyU_6wfCUPQjdHnvUZ5tcPmM_cC2g2b9oq-vAByIHnzV8ngN3Xc0nn09OedtdtlXkcXE85lLwcD-QZbsoRZ_6uV_iG3gkd_VFz9n0_Oz76SQdkiukHhHaAjVQIfgImfGBks9UPhhEgrRZJJi8Ub5SoPPC1I3PvG6gycrGmVI1AoLOqXtfsJ1u1oVXjKOZFwr7vITaKY2Ip5ClUL5QTuWhViFh71YKtfM-hoaN_77B2Kh5S5q3hUjYwUrddjUSrNAGIQR6XTJhR2MxTgJqruvC7A5lAN1QwNXnXzK6zEpAdxAS9rLvwbE2EpQm7Jowvda3owAF4V4v6drLGIwbEA8hyEzY-9Uo-KPq2xsp-0Gy_nA0l3a4ftXSaW-DFQhXNSCmRBVuuWmUJ9kcslLq1__R_n32WMakHsSkO2A7i5u78Aah1aI6jJPmFxfPI0Q
  priority: 102
  providerName: Scholars Portal
– databaseName: SpringerOpen (Open Access)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fa9swED5Gy2Avo-t-eeuKBmN78mb5ZEt-LNlKGGxPK_RhIGRZpmbDCW0K63_fO9kx9VLGIH6JzrF8J-W-kz7dAbyrdSOlRpWGvAlcwixLXYl16rUz6By5GMcHnL99L5dn6ut5cT6SaPgszGz_Hs0nz6waZmDhRw5y9sn9GmZuLcrFtJSSUUxOnnvMoLlz19zj7MDIXTbktCX6V_rQ6HJOD-DxiBXFyWDcJ_Ag9IfwcKgeefMUftLc5tm86erfQYzEDLFqxbpA4fpGLD-fLETXX3R15GUJ-qxzKcKfkfzaRyleuhf-hp4gIllraHoGZ6dffiyW6VgsIfWEuDapMjWBiZAZH7iYTO2DIWTHhz-CKVrla4W6KE3T-szrFtusap2pVCsx6ILN9Rz2-lUfXoIgty0V2bDCxilNCKbMK6l8qZwqQqNCAu-3CrXrISeGjXvZaGzUvGXN21ImcLRVtx2nxpWV2hAkoCgqT-Dt1EyDml_X9WF1TTJIYSXSv8m_ZHSVVUjhHSbwYrDg1JsclWYsmoCe2XYS4KTa85a-u4jJtZHwDYHGBD5sR8Gdrt__kvkwSOY_Tu7Pjt__6viyV8FKgp8aCSOSCu-5aZJn2QKzKtev_rsfr-FRHkt1MD_uCPY2l9fhDQGmTX0cp8stLloUlg
  priority: 102
  providerName: Springer Nature
Title Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression
URI https://link.springer.com/article/10.1038/cddis.2013.61
https://www.ncbi.nlm.nih.gov/pubmed/23470540
https://www.proquest.com/docview/1786146052
https://www.proquest.com/docview/1315632572
https://search.proquest.com/docview/1790939563
https://pubmed.ncbi.nlm.nih.gov/PMC3613839
http://kipublications.ki.se/Default.aspx?queryparsed=id:126473389
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_ajsFexr7nrTMajO3JiW3JlvzYeS1hkK6MFfIwELIsU9NWCWsK7X_fk_xBspY9DJJAoksi6e58v5N_0gF8qnidJJyyyKS1cSXM4kjltIo0V4IqhSFGuQ3O8-N8dsq-L7LFDmTDXhhP2tdVO7EXlxPbnnlu5epSTwee2PRkXlKMQRjYp7uwiwa6kaL7yy9m6BjH-_M0Yyqm2jFzHIuLTnJXGSaljMd-uWMzFN3Dl_dpkuO90r_OFfWx6OgZPO1BJDnoOvscdox9AY-7spK3L-E3Or1z83VbXRjSMzbIsiGrjBJlazL7dlCS1p61lSdsEXys0oSYm54Va72UW9Mn-hb_gXgWV9f0Ck6PDn-Vs6ivohBphGLriIkKUYaJhTauykyljUDI53aFGJE1TFeM8iwXdaNjzRvaxEWjRMGahBqeOT2-hj27tOYtEIznCUPlFrRWjCO0ydMiYTpnimWmZiaAz8OEylV3WIb0N7mpkF4J0ilB5kkA-8N0y95nrmTCBWIFTK_SAD6OzWjtbrjKmuU1ylDMNyleZv4lw4u4oJj30QDedBocezOoPgC-pdtRwJ22vd2CRuhP3e6NLoAvgxVsdP3hQaadkWz_OMZF2X9-3rqnvDIyQVzKKYJHnMIHvjTKO9mMxkXK3_33CN7Dk9TX9HBEun3YW_-5Nh8QWa2rEP1pwUN49PXw-OQnvivzMvSrFPg6ZyJ0S5g_Qu9vd1qhK4A
link.rule.ids 230,315,730,783,787,867,888,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,41132,42201,43322,43817,51588,53804,53806,74079,74636
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELWgCMEF8VlCWzASglNonHFi51RVhWqBtqdW2gOS5TiOGoGyC7uV6L9nxvGGLq0qJZd4kjgztufZfplh7F2tGiEUyNTnjacUZllqS6hTp6wGa9HFWPrB-fiknJzJr9NiGhfcFpFWuRoTw0DdzBytke8KpdGTIPjO9-a_UsoaRburMYXGXXaP4nBRBgM1VeMaS4aTdXTpMbRmBnrXEUmHCF3wsRTrrugavrxOkxz3Sv-LKxp80eFj9iiCSL4_WP0Ju-P7p-z-kFby8hn7jp2euvmyq396HhkbfNbyeQHc9g2ffNo_4F1_3tWBsMXxmOeC-z-RFdsHKVrT5-4S38ADi2soes7ODj-fHkzSmEUhdQjFlqnUNaIMn2nnKctM7bxGyEd_hXhdtNLVElRR6qZ1mVMttFnVWl3JVoBXBdnxBdvoZ71_yTj6cyHRuBU0ViqENmVeCelKaWXhG-kT9n6lUDMfgmWYsMkN2gTNG9K8KUXCtlfqNrHPLMw_Cyfs7ViMrZ0-1_Z-doEygPNNwGHmNhlVZRXgvA8StjlYcKxNDlIRSE2YWrPtKEDRttdL-u48RN0GBD6IJhP2YdUKrlT95o_Mh0ay_nD0iyZe_9HRaRbeCMSlChA8ogpvuGmUJ9kCsipXr25X4Rv2YHJ6fGSOvpx822IP85DEg5hz22xj-fvC7yCUWtavQ3_5C4vfH0c
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCNQL4k2ggJEQnMLGGSd2TqhqWS2vigOV9oBkOY6jRqDslt1K9N8z43gDS6tKm8t68poZez7bX2YYe1WrRggFMvV546mEWZbaEurUKavBWgwxlj5w_nJUzo7lx3kxj_ynVaRVbsbEMFA3C0dr5BOhNEYSBN_5pI20iK-H03fL05QqSNFOayyncZ3dUDhLIQ9XczWut2Q4ccfwHtNsZqAnjgg7RO6Ct6XYDksXsOZFyuS4b_pfjtEQl6Z32O0IKPn-4AF32TXf32M3hxKT5_fZdxwAqMuvu_qn55G9wRctXxbAbd_w2eH-Ae_6k64O5C2Ov2UuuP8dGbJ9kKL1fe7O8Q48MLqGpgfsePr-28EsjRUVUoewbJ1KXSPi8Jl2nirO1M5rhH_0hYjXRStdLUEVpW5alznVQptVrdWVbAV4VZBNH7KdftH7x4xjbBcSDV1BY6VCmFPmlZCulFYWvpE-Ya83CjXLIXGGCRveoE3QvCHNm1IkbG-jbhP7z8r8tXbCXo7N6Pn0urb3izOUAZx7Ag45V8moKqsA54CQsEeDBcenyUEqAqwJU1u2HQUo8_Z2S9-dhAzcgCAIkWXC3my84J9Hv_wl88FJti-OMdLE_390dJiVNwIxqgIEkqjCS04a5Um2gKzK1ZOrVfiC3cKuYj5_OPr0lO3moZ4Hkej22M7615l_hqhqXT8P3eUPDygjhQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incompatible+effects+of+p53+and+HDAC+inhibition+on+p21+expression+and+cell+cycle+progression&rft.jtitle=Cell+death+%26+disease&rft.au=Sachweh%2C+M+C+C&rft.au=Drummond%2C+C+J&rft.au=Higgins%2C+M&rft.au=Campbell%2C+J&rft.date=2013-03-01&rft.issn=2041-4889&rft.eissn=2041-4889&rft.volume=4&rft.spage=e533&rft.epage=e533&rft_id=info:doi/10.1038%2Fcddis.2013.61&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-4889&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-4889&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-4889&client=summon